|
Jul 17
|
GenSight Biologics Announces Publication on Predictors of Final Visual Outcome in Patients Treated with LUMEVOQ® Gene Therapy
|
|
Jun 26
|
GenSight Biologics Announces Significant Milestone in New Manufacturing Partnership with Catalent
|
|
Jun 12
|
GenSight Biologics Reaches Agreement with ANSM for Opening of LUMEVOQ® Named Early Access Program (AAC) in France
|
|
Mar 17
|
GenSight Biologics Announces LUMEVOQ® Scientific Updates at NANOS 2025
|
|
Oct 17
|
GenSight Biologics Announces LUMEVOQ® Scientific Updates at AAO 2024
|
|
Jun 20
|
GenSight Biologics Renegotiates Financial Obligations and Provides Operational Updates
|
|
Jan 16
|
Laurence Rodriguez, Appointed CEO of GenSight Biologics in December 2023, Joins the Company’s Board of Directors
|
|
Dec 27
|
GenSight Biologics Provides Business and Financial Update
|
|
Dec 22
|
GenSight Biologics appoints Laurence Rodriguez as Chief Executive Officer
|